Method for inhibiting bone resorption with an alendronate and vitamin D formulation

A pharmaceutical composition suitable for inhibiting abnormal bone resorption in a mammal, in need thereof, comprising a supplementary effective amount of from about 100 to about 60,000 IU of a non-activated metabolite of vitamin D2 and/or D3, and a pharmaceutically effective amount of from about 0.05 to about 560 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis.

A method for preventing or treating metabolic bone disease in a mammal, in need thereof, comprising concomitantly, orally administering to said mammal pharmaceutical compositions comprising a supplementary effective amount of a non-activated metabolite of vitamin D2 and/or D3, and a pharmaceutically effective amount of at least one bisphosphonate, as unit dosages, according to a continuous dosing schedule, wherein administration is performed, simultaneously or alternately, according to dosing intervals of once-weekly, twice-weekly, bi-weekly, once-monthly, and bi-monthly.

A method for preventing or treating abnormal bone resorption in a mammal, in need thereof, comprising orally administering to said mammal a pharmaceutical composition, comprising a supplementary effective amount of a non-activated metabolite of vitamin D2 and/or D3, and a pharmaceutically effective amount of at least one bisphosphonate, as a unit dosage according to a continuous administration schedule.

A method for preventing or treating abnormal bone resorption in a mammal, in need thereof, comprising orally administering to said mammal a pharmaceutical composition comprising a supplementary effective amount of from about 100 to about 60,000 IU of a non-activated metabolite of vitamin D2 and/or D3 and a pharmaceutically effective amount of from about 0.05 to about 560 mg of alendronate, pharmaceutcally acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

A pharmaceutical composition suitable for oral administration for the treatment or prevention of abnormal bone resorption in mammals, in need thereof, comprising a unit dosage of a supplementary effective amount of at least about 2,800 IU of a non-activated metabolite of vitamin D2 and/or D3, and a pharmaceutically effective amount of at least about 70 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, biweekly, monthly, and bimonthly.

A pharmaceutical composition suitable for oral administration for the treatment or prevention of abnormal bone resorption in mammals, in need thereof, comprising a unit dosage of a supplementary effective amount of at least about 5,600 IU of a non-activated metabolite of vitamin D2 and/or D3, and a pharmaceutically effective amount of at least about 70 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates s, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

A pharmaceutical composition suitable for oral administration for the treatment or prevention of abnormal bone resorption in mammals, in need thereof, comprising a unit dosage of a supplementary effective amount of at least about 2,800 IU of a non-activated metabolite of vitamin D2 and/or D3, and a pharmaceutically effective amount of at least about 35 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

A pharmaceutical composition suitable for oral administration for the treatment or prevention of abnormal bone resorption in mammals, in need thereof, comprising a unit dosage of a supplementary effective amount of at least about 5,600 IU of a non-activated metabolite of vitamin D2 and/or D3, and a pharmaceutically effective amount of at least about 35 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, biweekly, monthly, and bimonthly.

A method of preventing or treating abnormal bone resorption in a mammal, in need thereof, comprising orally administering to said mammal a pharmaceutical composition comprising a unit dosage of a supplementary effective amount of at least about 2,800 IU of a non-activated metabolite of vitamin D2 and/or D3 and a pharmaceutically effective amount of at least about 70 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

A method of preventing or treating abnormal bone resorption in a mammal, in need thereof, comprising orally administering to said mammal a pharmaceutical composition comprising a unit dosage of a supplementary effective amount of at least about 5,600 IU of a non-activated metabolite of vitamin D2 and/or D3 and a pharmaceutically effective amount of at least about 70 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

A method of preventing or treating abnormal bone resorption in a mammal, in need thereof, comprising orally administering to said mammal a pharmaceutical composition comprising a unit dosage of a supplementary effective amount of at least about 2,800 IU of a non-activated metabolite of vitamin D2 and/or D3 and a pharmaceutically effective amount of at least about 35 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

A method of preventing or treating abnormal bone resorption in a mammal, in need thereof, comprising orally administering to said mammal a pharmaceutical composition comprising a unit dosage of a supplementary effective amount of at least about 5,600 IU of a non-activated metabolite of vitamin D2 and/or D3 and a pharmaceutically effective amount of at least about 35 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

A pharmaceutical composition suitable for oral administration for the treatment or prevention of abnormal bone resorption in mammals, in need thereof, comprising a unit dosage of a supplementary effective amount of at least about 2,800 IU of a non-activated metabolite of vitamin D2 and/or D3, and a pharmaceutically effective amount of at least about 280 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

A pharmaceutical composition suitable for oral administration for the treatment or prevention of abnormal bone resorption in mammals, in need thereof, comprising a unit dosage of a supplementary effective amount of at least about 5,600 IU of a non-activated metabolite of vitamin D2 and/or D3, and a pharmaceutically effective amount of at least about 280 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

A method of preventing or treating abnormal bone resorption in a mammal, in need thereof, comprising orally administering to said mammal a pharmaceutical composition comprising a unit dosage of a supplementary effective amount of at least about 2,800 IU of a non-activated metabolite of vitamin D2 and/or D3 and a pharmaceutically effective amount of at least about 280 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

A method of preventing or treating abnormal bone resorption in a mammal, in need thereof, comprising orally administering to said mammal a pharmaceutical composition comprising a unit dosage of a supplementary effective amount of at least about 5,600 IU of a non-activated metabolite of vitamin D2 and/or D3 and a pharmaceutically effective amount of at least about 35 mg of alendronate, pharmaceutically acceptable salts, derivatives, hydrates, and mixtures thereof, on an alendronic acid active weight basis, wherein the dosing interval is once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.